Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Forodesine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Forodesine SCHEMBL8244721 | 0.99 | PNP (0.75) | PNPMTAP | |
| Forodesine SCHEMBL15740230 | 0.99 | PNP (0.75) | PNPMTAP | |
| Forodesine SCHEMBL506383 | 0.99 | PNP (0.75) | PNPMTAP | |
| Forodesine SCHEMBL8407141 | 0.99 | PNP (0.75) | PNPMTAP | |
| Hydrochloric Acid SCHEMBL4837679 | 0.89 | PNP (0.63) | PNPMTAP | |
| Galidesivir SCHEMBL30477706 | 0.86 | PNP (0.97) | PNPMTAP | |
| Galidesivir SCHEMBL29577672 | 0.86 | PNP (0.97) | PNPMTAP | |
| Galidesivir SCHEMBL15525360 | 0.86 | PNP (0.97) | PNPMTAP | |
| Galidesivir SCHEMBL4838048 | 0.86 | PNP (0.97) | PNPMTAP | |
| Galidesivir SCHEMBL23102311 | 0.85 | PNP (1.00) | PNPMTAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853224-B2 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2014-10-07 | — | — | US | disclosed |
| EP-2395005-A1 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | Industrial Research Limited (NZ) | 2011-12-14 | — | — | EP | disclosed |
| US-20110130412-A1 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | BIOCRYST PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130412-A1 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | PNP, TYMP, NTPCR | PNP 1/4885MTAP 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.